Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 4.81B 723M 647M 595M 539M 1.01B 68.62B 1.03B 7.1B 2.85B 36.09B 2.71B 2.65B 114B P/E 2026 *
6.37x
P/E 2027 * 5.93x
Enterprise Value 4.81B 723M 647M 595M 539M 1.01B 68.62B 1.03B 7.1B 2.85B 36.09B 2.71B 2.65B 114B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 2.05x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
1 day-21.87%
1 month-21.87%
3 months-12.78%
6 months-12.78%
Current year-12.78%
1 month 16.79
Extreme 16.79
21.78
Current year 16.79
Extreme 16.79
22.23
1 year 16.79
Extreme 16.79
22.23
3 years 16.79
Extreme 16.79
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 2019-11-30
Comptroller/Controller/Auditor 53 2011-01-31
Director TitleAgeSince
Chairman 70 2002-08-13
Director/Board Member 58 -
Director/Board Member 50 2020-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-21.87%-.--% - - 723M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average -0.31%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.00%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 2.34B 352M 315M 290M 263M 491M 33.44B 501M 3.46B 1.39B 17.59B 1.32B 1.29B 55.47B 2.35B 353M 316M 290M 263M 492M 33.48B 501M 3.46B 1.39B 17.61B 1.32B 1.3B 55.54B
Net income 755M 113M 102M 93.45M 84.67M 158M 10.77B 161M 1.11B 447M 5.67B 426M 417M 17.87B 811M 122M 109M 100M 90.95M 170M 11.57B 173M 1.2B 481M 6.09B 457M 448M 19.19B
Net Debt - -
Projected Income Statement - Annual - China Shineway Pharmaceutical Group Limited
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - China Shineway Pharmaceutical Group Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.367CNY
Average target price
7.294CNY
Spread / Average Target
+14.56%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Shineway Pharmaceutical Group Limited